CIPLA.NS - Cipla Limited

NSE - NSE Real Time Price. Currency in INR
601.40
-8.85 (-1.45%)
At close: 3:29PM IST
Stock chart is not supported by your current browser
Previous Close610.25
Open610.15
Bid0.00 x 0
Ask0.00 x 0
Day's Range599.00 - 613.50
52 Week Range480.20 - 663.40
Volume1,088,421
Avg. Volume1,455,500
Market Cap484.094B
BetaN/A
PE Ratio (TTM)42.34
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Does Cipla Limited’s (NSE:CIPLA) Past Performance Indicate A Stronger Future?
    Simply Wall St.13 days ago

    Does Cipla Limited’s (NSE:CIPLA) Past Performance Indicate A Stronger Future?

    When Cipla Limited (NSEI:CIPLA) released its most recent earnings update (30 September 2017), I wanted to understand how these figures stacked up against its past performance. The two benchmarks IRead More...

  • Is Cipla Limited (NSE:CIPLA) As Financially Strong As Its Balance Sheet Indicates?
    Simply Wall St.28 days ago

    Is Cipla Limited (NSE:CIPLA) As Financially Strong As Its Balance Sheet Indicates?

    Stocks with market capitalization between $2B and $10B, such as Cipla Limited (NSEI:CIPLA) with a size of ₹476.25B, do not attract as much attention from the investing community as doRead More...

  • Yes Bank, IndusInd to join India's BSE Sensex index; Lupin, Cipla dropped
    Reuters2 months ago

    Yes Bank, IndusInd to join India's BSE Sensex index; Lupin, Cipla dropped

    (Reuters) - Indian private sector lenders Yes Bank Ltd and IndusInd Bank Ltd will join the BSE stock exchange's 30-member Sensex index, effective Dec. 18, the index provider said on Friday. Drugmakers ...

  • Reuters2 months ago

    Cipla second-quarter profit up 19 percent on higher domestic sales

    (Reuters) - Cipla Ltd, India's second largest drugmaker by market capitalisation, posted its second straight rise in quarterly profit, slightly above analysts' estimate, boosted by strong domestic sales. ...

  • Reuters5 months ago

    Morning News Call - India, August 14

    To access the newsletter, click on the link: http://share.thomsonreuters.com/assets/newsletters/Indiamorning/MNC_IN_08142017.pdf If you would like to receive this newsletter via email, please register ...

  • Reuters11 months ago

    India's Cipla looks to boost US business as Q3 profit beats estimates

    Indian drugmaker Cipla Ltd's third-quarter profit beat estimates due to higher sales in the United States, and the company said it was looking for licensing deals and acquisitions to build its speciality medicines pipeline in that market. The country's fifth-largest drugmaker by sales reported a roughly 21 percent rise in revenue from North America for the October-December period. Cipla bought two U.S. generic drug producers, Invagen and Exelan, for about $550 million last year in its first big move to expand in a market where most of its local peers already have a large presence.